

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LEPU BIOPHARMA CO., LTD.

樂普生物科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2157)

POLL RESULTS OF THE 2024 FIRST EXTRAORDINARY GENERAL MEETING HELD ON JANUARY 31, 2024

References are made to the notice (the “**Notice**”) and the circular (the “**Circular**”) of the 2024 first extraordinary general meeting (the “**EGM**”) of the Company both dated January 16, 2024. Capitalised terms used herein shall have the same meanings as those defined in the Notice and the Circular unless the context requires otherwise.

ATTENDANCE AT THE EGM

The EGM was chaired by Dr. Pu Zhongjie, the chairman of the Board and an executive Director, and was successfully held at Conference Room, Building 7, No. 37 Chaoqian Road, Changping District, Beijing, the PRC on Wednesday, January 31, 2024 at 10:30 a.m.. The EGM was convened in accordance with the requirements of the relevant laws and regulations of the PRC and the Articles of Association, and the poll results of the EGM are lawful and valid.

The Board is pleased to announce that all the resolutions proposed at the EGM as set out in the Notice were duly passed by the Shareholders by way of poll at the EGM.

POLL RESULTS OF THE EGM

The poll results in respect of all the resolutions proposed at the EGM are as follows:

ORDINARY RESOLUTION		NO. OF SHARES VOTED (%)		
		FOR	AGAINST	ABSTAIN
1.	THAT:			
	(a) The framework agreement dated November 13, 2023 (the “ CDMO Services Framework Agreement ”) and the supplemental framework agreement dated December 22, 2023 (the “ Supplemental CDMO Services Framework Agreement ”) entered into between the Company and Lepu Medical Technology (Beijing) Co., Ltd. (樂普(北京)醫療器械股份有限公司) (copies of which have been produced at the EGM marked “A” and “B” respectively and initialed by the chairman of the EGM for the purpose of identification), all transactions contemplated thereunder, and the proposed cap of such transactions (as particularised in the Supplemental CDMO Services Framework Agreement), be and are hereby approved, confirmed and ratified; and	513,649,596 (99.973214%)	0 (0%)	137,621 (0.026786%)
	(b) The directors of the Company be and are hereby authorised to take all such steps, do all such acts and/or things and/or execute all such documents incidental to, ancillary to or in connection with matters contemplated in or relating to the CDMO Services Framework Agreement (as supplemented by the Supplemental CDMO Services Framework Agreement) and all transactions contemplated thereunder as they may in their absolute discretion consider necessary, appropriate, desirable or expedient to give effect to the CDMO Services Framework Agreement (as supplemented by the Supplemental CDMO Services Framework Agreement) and the implementation of all transactions contemplated thereunder.	513,649,596 (99.973214%)	0 (0%)	137,621 (0.026786%)

As more than one-half of the votes were cast in favour of the resolution numbered 1 above, this resolution was duly passed as an ordinary resolution of the Company.

Notes:

1. As at the date of the EGM, the total number of issued ordinary Shares was 1,659,444,838 Shares (including 1,605,176,474 H Shares and 54,268,364 Domestic Shares).
2. As at the date of the EGM, Lepu Medical and Ningbo Houde Yimin held an aggregate of 658,591,549 Shares, representing approximately 39.69% of the issued Shares, and were required to abstain from voting at the EGM. Save as disclosed, there were no Shareholders, who, pursuant to Rule 13.40 of the Listing Rules, were required to abstain from voting in favour of any of the proposed resolutions at the EGM, nor were there any Shareholders who were required under the Listing Rules to abstain from voting. Accordingly, the total number of Shares entitling the Shareholders to attend and vote at the EGM was 1,000,853,289 Shares, representing approximately 60.31% of the issued Shares.
3. None of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the resolution at the EGM.
4. The total number of issued Shares held by the Shareholders in person or their proxies who have attended the EGM and are entitled to vote is 513,787,217 Shares, representing approximately 30.96% of the total number of issued Shares as at the date of the EGM.
5. The Company's H Shares registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the EGM for the purpose of vote-taking.
6. All Directors attended the EGM in person or via electronic means.

By order of the Board
Lepu Biopharma Co., Ltd.
Dr. Pu Zhongjie
Chairman of the Board and Executive Director

Shanghai, the PRC
January 31, 2024

As at the date of this announcement, the Board comprises Dr. Pu Zhongjie (chairman) and Dr. Sui Ziye (chief executive officer) as executive Directors; Mr. Yang Hongbing and Ms. Pu Jue as non-executive Directors; and Mr. Zhou Demin, Mr. Yang Haifeng and Mr. Fengmao Hua as independent non-executive Directors.